Faegre Drinker represented Allievex Corp., a Boston-based biopharmaceutical company, in connection with its formation and significant venture capital financing rounds. Jon Zimmerman led the corporate deal team. The initial financing round, which occurred in October 2019, involved the simultaneous in-licensing from BioMarin Pharmaceutical Inc. of exclusive worldwide rights to develop and commercialize an enzyme replacement therapy to treat mucopolysaccharidosis type IIIB (MPS IIIB), a rare pediatric neurodegenerative disease.
Dan Boeglin led the technology transaction team for the in-license. Faegre Drinker also represented Allievex when it followed this transaction with a successful second financing round in July 2020, which raised additional funds for the company from new and existing investors.
